Recommendation of the President – Enspryng (satralizumab)
On 1 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 104/2024 on the evaluation of the drug Enspryng (satralizumab) under the drug program: B.138.FM. Treatment of patients with neuritis and myelitis spectrum disorder (NMOSD) (ICD-10: G.36.0)